{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T11:41:36Z","timestamp":1784374896698,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA23766"],"award-info":[{"award-number":["P01 CA23766"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jtct.2024.12.010","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T11:46:38Z","timestamp":1734435998000},"page":"105.e1-105.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Letermovir for Prevention of Recurrent Cytomegalovirus in High-Risk Allogeneic Hematopoietic Cell Transplantation Recipients"],"prefix":"10.1016","volume":"31","author":[{"given":"Gyuri","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon Joo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parastoo B.","family":"Dahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Tamari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boglarka","family":"Gyurkocza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann A.","family":"Jakubowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza B.","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Shaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karam M.","family":"Obeid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo-Anne H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genovefa A.","family":"Papanicolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2024.12.010_bib0001","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.idc.2010.01.008","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients","volume":"24","author":"Ljungman","year":"2010","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.jtct.2024.12.010_bib0002","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/cid\/ciz490","article-title":"A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation","volume":"70","author":"Ljungman","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2024.12.010_bib0003","first-page":"965","article-title":"Letermovir prophylaxis for cytomegalovirus","volume":"378","author":"Marty","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2024.12.010_bib0004","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3026(23)00344-7","article-title":"Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Russo","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2024.12.010_bib0005","doi-asserted-by":"crossref","first-page":"ofac687","DOI":"10.1093\/ofid\/ofac687","article-title":"Real-world outcomes associated with letermovir use for cytomegalovirus primary prophylaxis in allogeneic hematopoietic cell transplant recipients: a systematic review and meta-analysis of observational studies","volume":"10","author":"Vyas","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jtct.2024.12.010_bib0006","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/ciab1064","article-title":"Impact of letermovir primary cytomegalovirus prophylaxis on 1-year mortality after allogeneic hematopoietic cell transplantation: a retrospective cohort study","volume":"75","author":"Su","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2024.12.010_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2024.05.021","article-title":"Impact of primary letermovir prophylaxis versus preemptive antiviral therapy for cytomegalovirus on economic and clinical outcomes after hematopoietic cell transplantation","volume":"30","author":"Tan","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.12.010_bib0008","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1182\/blood.V99.12.4357","article-title":"High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution","volume":"99","author":"Chakrabarti","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.12.010_bib0009","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1182\/blood-2007-05-092130","article-title":"Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing","volume":"110","author":"Komanduri","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.12.010_bib0010","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1182\/blood-2002-05-1387","article-title":"Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells","volume":"100","author":"Ozdemir","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.12.010_bib0011","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.2020009396","article-title":"Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation","volume":"138","author":"Zamora","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.12.010_bib0012","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jtct.2021.05.001","article-title":"American Society for Transplantation and Cellular Therapy Series: #3-Prevention of cytomegalovirus infection and disease after hematopoietic cell transplantation","volume":"27","author":"Hakki","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.12.010_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2021.09.015","article-title":"Post-transplantation cyclophosphamide is associated with an increase in non-cytomegalovirus herpesvirus infections in patients with acute leukemia and myelodysplastic syndrome","volume":"28","author":"Singh","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.12.010_bib0014","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jtct.2021.09.010","article-title":"American Society for Transplantation and Cellular Therapy Series: #4 - Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation","volume":"27","author":"Yong","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.12.010_bib0015","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/QCO.0000000000000170","article-title":"Approach to drug-resistant cytomegalovirus in transplant recipients","volume":"28","author":"Chou","year":"2015","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.jtct.2024.12.010_bib0016","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bjh.12363","article-title":"Management of cytomegalovirus infection in haemopoietic stem cell transplantation","volume":"162","author":"Emery","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2024.12.010_bib0017","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.bbmt.2020.01.027","article-title":"Letermovir for secondary prophylaxis of cytomegalovirus infection and disease after allogeneic hematopoietic cell transplantation: results from the french compassionate program","volume":"26","author":"Robin","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.010_bib0018","doi-asserted-by":"crossref","first-page":"e13187","DOI":"10.1111\/tid.13187","article-title":"Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: real-world experience","volume":"21","author":"Lin","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jtct.2024.12.010_bib0019","article-title":"Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 Update from the Transplant Associated Virus Infections Forum","author":"Ljungman","year":"202479787","journal-title":"Clin Infect Dis"},{"issue":"2 Suppl","key":"10.1016\/j.jtct.2024.12.010_bib0020","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.bbmt.2014.12.034","article-title":"Reprint of: Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies","volume":"21","author":"Boeckh","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.010_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M13-2729","article-title":"Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial","volume":"162","author":"Boeckh","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtct.2024.12.010_bib0022","doi-asserted-by":"crossref","first-page":"e13054","DOI":"10.1111\/tid.13054","article-title":"Use of maintenance therapy and incidence of recurrent Cytomegalovirus DNAemia among allogeneic hematopoietic cell transplant recipients","volume":"21","author":"Camargo","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jtct.2024.12.010_bib0023","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2024.12.010_bib0024","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1182\/bloodadvances.2021004362","article-title":"Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients","volume":"5","author":"Hill","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2024.12.010_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.05.020","article-title":"Letermovir discontinuation at day 100 after allogeneic stem cell transplant is associated with increased CMV-related mortality","volume":"28","author":"Liu","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.12.010_bib0026","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1182\/bloodadvances.2021005637","article-title":"Letermovir prophylaxis in T-cell-depleted transplants: breakthrough and rebound infections in the postmarketing setting","volume":"5","author":"Marzolini","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2024.12.010_bib0027","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.bbmt.2020.06.025","article-title":"Impact of preemptive therapy for cytomegalovirus on hospitalizations and cost after hematopoietic stem cell transplantation","volume":"26","author":"Fang","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.010_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.04.016","article-title":"Outcomes of refractory cytomegalovirus infection in the first year after allogeneic hematopoietic cell transplantation","volume":"28","author":"Karantoni","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.12.010_bib0029","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.bbmt.2020.03.019","article-title":"Impact of preemptive therapy for cytomegalovirus on toxicities after allogeneic hematopoietic cell transplantation in clinical practice: a retrospective single-center cohort study","volume":"26","author":"Zavras","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.010_bib0030","doi-asserted-by":"crossref","first-page":"e13687","DOI":"10.1111\/tid.13687","article-title":"Letermovir treatment of cytomegalovirus infection or disease in solid organ and hematopoietic cell transplant recipients","volume":"23","author":"Linder","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jtct.2024.12.010_bib0031","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/INF.0000000000004208","article-title":"Pharmacokinetics, safety, and efficacy of letermovir for cytomegalovirus prophylaxis in adolescent hematopoietic cell transplantation recipients","volume":"43","author":"Groll","year":"2024","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jtct.2024.12.010_bib0032","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1128\/AAC.01623-15","article-title":"Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance","volume":"59","author":"Chou","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jtct.2024.12.010_bib0033","doi-asserted-by":"crossref","first-page":"e13619","DOI":"10.1111\/tid.13619","article-title":"Cytomegalovirus events in high-risk allogeneic hematopoietic-cell transplantation patients who received letermovir prophylaxis","volume":"23","author":"Chen","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jtct.2024.12.010_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.01.008","article-title":"Human cytomegalovirus-specific T-cell reconstitution and late-onset cytomegalovirus infection in hematopoietic stem cell transplantation recipients following letermovir prophylaxis","volume":"28","author":"Gabanti","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.12.010_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2021.03.003","article-title":"Cytomegalovirus prophylaxis versus pre-emptive strategy: different CD4(+) and CD8(+) T cell reconstitution after allogeneic hematopoietic stem cell transplantation","volume":"27","author":"Sperotto","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.12.010_bib0036","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1182\/blood-2015-03-631853","article-title":"CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRbeta repertoire","volume":"125","author":"Suessmuth","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.12.010_bib0037","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1093\/cid\/ciz1210","article-title":"Cytomegalovirus (CMV) cell-mediated immunity and CMV infection after allogeneic hematopoietic cell transplantation: the REACT study","volume":"71","author":"Chemaly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2024.12.010_bib0038","first-page":"2062","article-title":"How I prevent viral reactivation in high-risk patients","volume":"141","author":"Dadwal","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.12.010_bib0039","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.bbmt.2016.05.003","article-title":"Cytomegalovirus infection after CD34(+)-selected hematopoietic cell transplantation","volume":"22","author":"Huang","year":"2016","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672400811X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672400811X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T03:02:05Z","timestamp":1769914925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663672400811X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S266663672400811X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.12.010","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Letermovir for Prevention of Recurrent Cytomegalovirus in High-Risk Allogeneic Hematopoietic Cell Transplantation Recipients","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}